News und Analysen
EQS-Adhoc: Eckert & Ziegler Achieves Double-Digit Growth in Q3 versus Previous Year. Significant Jump in Sales also in First 9 Months, Earnings still Burdened by Special Items Compared to Same Period Last Year.
EQS-Adhoc: Eckert & Ziegler Achieves Double-Digit Growth in Q3 versus Previous Year. Significant Jump in Sales also in First 9 Months, Earnings still Burdened by Special Items Compared to Same Period Last Year.
EQS-News: Eckert & Ziegler and PharmaLogic Sign Reservation Agreement for Supply of Therapeutic Radioisotope Actinium-225
EQS-News: Eckert & Ziegler and PharmaLogic Sign Reservation Agreement for Supply of Therapeutic Radioisotope Actinium-225
EQS-News: Eckert & Ziegler Receives Award for Professional Training
EQS-News: Eckert & Ziegler Receives Award for Professional Training
EQS-Adhoc: Eckert & Ziegler Signs Strategically Important Agreement for the Supply of Lutetium-177 with POINT Biopharma
EQS-Adhoc: Eckert & Ziegler Signs Strategically Important Agreement for the Supply of Lutetium-177 with POINT Biopharma
EQS-News: Eckert & Ziegler collaborates with RefleXion Medical and Telix Pharmaceuticals to Expand Treatment Options for Prostate Cancer Patients
EQS-News: Eckert & Ziegler collaborates with RefleXion Medical and Telix Pharmaceuticals to Expand Treatment Options for Prostate Cancer Patients
EQS-News: Eckert & Ziegler Continues Positive Sales Development in the First Half of 2023
EQS-News: Eckert & Ziegler Continues Positive Sales Development in the First Half of 2023
EQS-Adhoc: Eckert & Ziegler again achieves sales growth compared to the previous year and confirms its forecast for 2023. Decline in earnings compared to same period last year due to extraordinary items.
EQS-Adhoc: Eckert & Ziegler again achieves sales growth compared to the previous year and confirms its forecast for 2023. Decline in earnings compared to same period last year due to extraordinary items.
EQS-News: Eckert & Ziegler: PentixaPharm Receives BfArM-Clearance for its Therapeutic to conduct a Clinical Trial in Lymphoma
EQS-News: Eckert & Ziegler: PentixaPharm Receives BfArM-Clearance for its Therapeutic to conduct a Clinical Trial in Lymphoma
EQS-News: ckert & Ziegler: Annual General Meeting Approves Dividend of EUR 0.50 per Share. Reorganization of the Executive Board, Supervisory Board and Group Executive Committee.
EQS-News: ckert & Ziegler: Annual General Meeting Approves Dividend of EUR 0.50 per Share. Reorganization of the Executive Board, Supervisory Board and Group Executive Committee.
EQS-News: Eckert & Ziegler to Host First Radionuclide Theranostics Forum in Boston, MA
EQS-News: Eckert & Ziegler to Host First Radionuclide Theranostics Forum in Boston, MA
EQS-News: Reorganization in the Executive Board of Eckert & Ziegler
EQS-News: Reorganization in the Executive Board of Eckert & Ziegler
EQS-News: Eckert & Ziegler with Strong Sales Growth in the First Quarter of 2023
EQS-News: Eckert & Ziegler with Strong Sales Growth in the First Quarter of 2023
EQS-News: Eckert & Ziegler: Recognized Australian Endocrine & Hypertension Center Joins International Groups with a Clinical Trial of PentixaPharm’s Primary Aldosteronism Lead Candidate
EQS-News: Eckert & Ziegler: Recognized Australian Endocrine & Hypertension Center Joins International Groups with a Clinical Trial of PentixaPharm’s Primary Aldosteronism Lead Candidate
EQS-Adhoc: Eckert & Ziegler Publishes Preliminary Figures for Q1/2023 with Double-digit Sales Growth, Earnings Decline and Confirmation of 2023 Full-Year Guidance
EQS-Adhoc: Eckert & Ziegler Publishes Preliminary Figures for Q1/2023 with Double-digit Sales Growth, Earnings Decline and Confirmation of 2023 Full-Year Guidance
EQS-News: Eckert & Ziegler Receives Manufacturing Authorization for GMP-grade Lutetium-177
EQS-News: Eckert & Ziegler Receives Manufacturing Authorization for GMP-grade Lutetium-177
EQS-News: Eckert & Ziegler Receives Environmental Approval for Jintan Radioisotope Site
EQS-News: Eckert & Ziegler Receives Environmental Approval for Jintan Radioisotope Site
EQS-News: Eckert & Ziegler to Supply POINT Biopharma with Actinium-225
EQS-News: Eckert & Ziegler to Supply POINT Biopharma with Actinium-225
EQS-News: Eckert & Ziegler: Successful fiscal year 2022
EQS-News: Eckert & Ziegler: Successful fiscal year 2022
EQS-News: Eckert & Ziegler Plans Change of Legal Form to European Stock Corporation (SE)
EQS-News: Eckert & Ziegler Plans Change of Legal Form to European Stock Corporation (SE)
EQS-News: Eckert & Ziegler with Unchanged Dividend Proposal
EQS-News: Eckert & Ziegler with Unchanged Dividend Proposal
EQS-News: Eckert & Ziegler Submits Drug Master File for Lu-177 n.c.a.
EQS-News: Eckert & Ziegler Submits Drug Master File for Lu-177 n.c.a.
EQS-News: Lausanne University Hospital Investigates Use of PENTIXAFOR in Cardio-Vascular Setting
EQS-News: Lausanne University Hospital Investigates Use of PENTIXAFOR in Cardio-Vascular Setting
EQS-Adhoc: Eckert & Ziegler Exceeds Forecast for the 2022 Financial Year According to Preliminary Figures
EQS-Adhoc: Eckert & Ziegler Exceeds Forecast for the 2022 Financial Year According to Preliminary Figures
EQS-News: Change in the Supervisory Board of Eckert & Ziegler AG
EQS-News: Change in the Supervisory Board of Eckert & Ziegler AG
EQS-Adhoc: Changes in the Management Board of Eckert & Ziegler
EQS-Adhoc: Changes in the Management Board of Eckert & Ziegler